Tiaa, Fsb Novo Cure LTD Transaction History

Tiaa, Fsb

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 11, 2022	SELL	$67.99 - $89.57 $747 - $985	-11 Reduced 0.37%	2,935 $223,000
Q2 2022 Aug 09, 2022	BUY	$56.6 - $89.9 $166,743 - $264,845	2,946 New	2,946 $205,000
Q3 2021 Oct 14, 2021	SELL	$116.17 - $194.55 $1.6 Million - $2.67 Million	-13,741 Closed	0 $0
Q4 2020 Jan 21, 2021	BUY	$112.16 - $174.14 $1.54 Million - $2.39 Million	13,741 New	13,741 $2.38 Million
Q2 2019 Aug 14, 2019	SELL	$42.22 - $63.23 $580,145 - $868,843	-13,741 Closed	0 $0
Q4 2018 Apr 15, 2019	BUY	$28.72 - $52.63 $394,641 - $723,188	13,741 New	13,741 $460,000
Q4 2018 Feb 22, 2019	SELL	$28.72 - $52.63 $394,641 - $723,188	-13,741 Closed	0 $0
Q3 2017 Oct 24, 2017	BUY	$18.05 - $21.75 $248,025 - $298,866	13,741	13,741 $273,000

262

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.03B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Tiaa, Fsb, based on Form 13F filings with the SEC.

Stay updated on Tiaa, Fsb with notifications on news.